# The serial use of PET- CT can contribute to risk assessment and the prediction of outcome in patients with multiple myeloma

Fluorine-18

- Fluorine-18 fluorodeoxyglucose positron emission tomography with computed tomography (FDG PET-CT)

- **596** Patients with multiple myeloma (age ≥ 65 years)

- Detection of **focal lesions (FLs)**: areas measuring ≥ 1 cm

Time points:
Presentation
Day 7
Post transplant
End of induction
Maintenance

	FL (*n*)	3-yr estimated PFS% (95% CI)	3-yr estimated OS% (95% CI)
Presentation	0	74	89
	1-3	74	85
	>3	59	72
Day 7	0	76	89
	1-3	72	86
	>3	53	72

- The presence of > 3 FLs detected on PET-CT at baseline and at later time points is associated with adverse progression free survival (PFS) and overall survival (OS)

Suppression of PET-CT FL activity

- **28%** Day 7
- **46%** End of induction

- These patients have a similar outcomes compared to patients who had no FLs at diagnosis